Immune efficacy of an adenoviral vector-based swine influenza vaccine against antigenically distinct H1N1 strains in mice

Wu, Yixuan; Yang, Dawei; Xu, Biao; Liang, Wenhua; Sui, Jinyu; Yan, Chen; Yang, Huanliang; Chen, Hualan; Wei, Ping; Qiao, Chuanling

doi:10.1016/j.antiviral.2017.09.009

Cited by 7 publications

(6 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The H1 subtype SIV standard antigen was kindly provided by the influenza group of the Harbin Veterinary Research Institute. A Hemagglutination Inhibition (HI) assay was performed as described elsewhere [ 16 ]. Briefly, 25 μL of eight HA units of the EA H1N1 antigen was mixed with 25 μL of two-fold serially diluted pig serum after incubating for 30 min.…”

Section: Methodsmentioning

confidence: 99%

Prevalence, Genetics and Evolutionary Properties of Eurasian Avian-like H1N1 Swine Influenza Viruses in Liaoning

Leng

Tang

et al. 2022

Viruses

View full text Add to dashboard Cite

Swine influenza virus (SIV) is an important zoonosis pathogen. The 2009 pandemic of H1N1 influenza A virus (2009/H1N1) highlighted the importance of the role of pigs as intermediate hosts. Liaoning province, located in northeastern China, has become one of the largest pig-farming areas since 2016. However, the epidemiology and evolutionary properties of SIVs in Liaoning are largely unknown. We performed systematic epidemiological and genetic dynamics surveillance of SIVs in Liaoning province during 2020. In total, 33,195 pig nasal swabs were collected, with an SIV detection rate of 2%. Our analysis revealed that multiple subtypes of SIVs are co-circulating in the pig population in Liaoning, including H1N1, H1N2 and H3N2 SIVs. Furthermore, 24 H1N1 SIVs were confirmed to belong to the EA H1N1 lineage and divided into two genotypes. The two genotypes were both triple reassortant, and the predominant one with polymerase, nucleoprotein (NP), and matrix protein (M) genes originating from 2009/H1N1; hemagglutinin (HA) and neuraminidase (NA) genes originating from EA H1N1; and the nonstructural protein (NS) gene originating from triple reassortant H1N2 (TR H1N2) was detected in Liaoning for the first time. According to our evolutionary analysis, the EA H1N1 virus in Liaoning will undergo further genome variation.

show abstract

Section: Methodsmentioning

confidence: 99%

Prevalence, Genetics and Evolutionary Properties of Eurasian Avian-like H1N1 Swine Influenza Viruses in Liaoning

Leng

Tang

et al. 2022

Viruses

View full text Add to dashboard Cite

show abstract

“…The administration of novel vaccine types including adenovirus vectors ( 99 , 100 ), subviral particles ( 101 ), and recombinant protein antigens ( 102 ) in combination with conventional influenza vaccines has been reported to enhance seroconversion and antibody cross-reactivity. Wang et al ( 103 ) demonstrated that a primary HA DNA vaccine followed by a seasonal trivalent inactivated vaccine (TIV) boost induced significantly higher antibody titres compared to two doses of either DNA vaccine or TIV in rabbits.…”

Section: Prime-boost Strategiesmentioning

confidence: 99%

A Review of DNA Vaccines Against Influenza

2018

View full text Add to dashboard Cite

The challenges of effective vaccination against influenza are gaining more mainstream attention, as recent influenza seasons have reported low efficacy in annual vaccination programs worldwide. Combined with the potential emergence of novel influenza viruses resulting in a pandemic, the need for effective alternatives to egg-produced conventional vaccines has been made increasingly clear. DNA vaccines against influenza have been in development since the 1990s, but the initial excitement over success in murine model trials has been tempered by comparatively poor performance in larger animal models. In the intervening years, much progress has been made to refine the DNA vaccine platform—the rational design of antigens and expression vectors, the development of novel vaccine adjuvants, and the employment of innovative gene delivery methods. This review discusses how these advances have been applied in recent efforts to develop an effective influenza DNA vaccine.

show abstract

“…Additional work is needed to explore whether Ad vector-based influenza vaccines could be used in all segments of the population. The use of the prime-boost approach with two different Ad vectors [54,141], Ad and another viral vector [142][143][144][145][146][147], or Ad vector and DNA immunization [148][149][150][151] will confer a considerably higher level of immune responses, especially in the elderly. Author Contributions: All authors have read and agreed to the published version of the manuscript.…”

Section: Discussionmentioning

confidence: 99%

Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines

et al. 2020

View full text Add to dashboard Cite

Ever since the discovery of vaccines, many deadly diseases have been contained worldwide, ultimately culminating in the eradication of smallpox and polio, which represented significant medical achievements in human health. However, this does not account for the threat influenza poses on public health. The currently licensed seasonal influenza vaccines primarily confer excellent strain-specific protection. In addition to the seasonal influenza viruses, the emergence and spread of avian influenza pandemic viruses such as H5N1, H7N9, H7N7, and H9N2 to humans have highlighted the urgent need to adopt a new global preparedness for an influenza pandemic. It is vital to explore new strategies for the development of effective vaccines for pandemic and seasonal influenza viruses. The new vaccine approaches should provide durable and broad protection with the capability of large-scale vaccine production within a short time. The adenoviral (Ad) vector-based vaccine platform offers a robust egg-independent production system for manufacturing large numbers of influenza vaccines inexpensively in a short timeframe. In this review, we discuss the progress in the development of Ad vector-based influenza vaccines and their potential in designing a universal influenza vaccine.

show abstract

Immune efficacy of an adenoviral vector-based swine influenza vaccine against antigenically distinct H1N1 strains in mice

Cited by 7 publications

References 37 publications

Prevalence, Genetics and Evolutionary Properties of Eurasian Avian-like H1N1 Swine Influenza Viruses in Liaoning

Prevalence, Genetics and Evolutionary Properties of Eurasian Avian-like H1N1 Swine Influenza Viruses in Liaoning

A Review of DNA Vaccines Against Influenza

Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines

Contact Info

Product

Resources

About